-
2 months ago | 
jdsupra.com | Brigid DeCoursey Bondoc |Adam L. Braverman |Kate Driscoll
In 2024, as in years past, healthcare fraud enforcement by the U.S. Department of Justice (DOJ) was substantial. Federal actions under the False Claims Act (FCA) alone resulted in $1.67 billion in settlements and judgments from managed care providers, hospitals and other medical facilities, pharmacies, pharmaceutical companies, laboratories, and physicians.
-
Jan 22, 2025 | 
jdsupra.com | Brigid DeCoursey Bondoc |Adam L. Braverman |Kate Driscoll
The Department of Justice published its False Claims Act (FCA) statistics for Fiscal Year 2024 this month, revealing a nearly 40% increase in whistleblower filings, increased recoveries year over year, and a near record number of settlements and judgments. Key takeaways include the following: FCA settlements and judgments exceeded $2.9 billion in FY 2024, an increase from the $2.68 billion recovered in FY 2023.
-
Mar 4, 2024 | 
jdsupra.com | Kate Driscoll |Nathaniel Mendell
Artificial Intelligence (AI), specifically generative AI technologies, hold significant promise for improving the healthcare industry by streamlining clinical operations, freeing service providers from mundane tasks, and diagnosing life-threatening diseases. But everyone—AI developers and users, lawmakers and enforcers alike—recognizes that AI can be used for improper purposes, too, including fraud and abuse.
-
Mar 4, 2024 | 
lexology.com | Kate Driscoll |Nathaniel Mendell
Artificial Intelligence (AI), specifically generative AI technologies, hold significant promise for improving the healthcare industry by streamlining clinical operations, freeing service providers from mundane tasks, and diagnosing life-threatening diseases. But everyone—AI developers and users, lawmakers and enforcers alike—recognizes that AI can be used for improper purposes, too, including fraud and abuse.
-
Jan 10, 2024 | 
jdsupra.com | Brigid DeCoursey Bondoc |Adam L. Braverman |Kate Driscoll
The year 2023 was a busy one for regulatory, compliance, and enforcement developments in the healthcare and life sciences industries, and 2024 promises to be even busier.
-
Jan 10, 2024 | 
lexology.com | Adam L. Braverman |Kate Driscoll |Nathaniel Mendell |Brigid DeCoursey Bondoc
The year 2023 was a busy one for regulatory, compliance, and enforcement developments in the healthcare and life sciences industries, and 2024 promises to be even busier.
-
Aug 25, 2023 | 
mondaq.com | Kate Driscoll
Kate Driscoll was a guest on the American Bar Association's
Voices in Health Law podcast, discussing the nature of
clinical trials fraud, recent developments in enforcement activity,
and the role of lawyers in counseling compliance by clinical
research organizations.
Listen to the podcast.
Because of the generality of this update, the information
provided herein may not be applicable in all situations and should
not be acted upon without specific legal advice based on particular
situations.
-
Aug 23, 2023 | 
mondaq.com | Kate Driscoll
Kate Driscoll spoke to Law.com about her experience on
secondment at Morrison Foerster client McKinsey & Company,
where Kate covered for associate general counsel Veronica Ip while
she was on parental leave. In a joint interview with Veronica, Kate
discussed what attracted her to the opportunity, the logistics of
the arrangement, and how both she and Morrison Foerster benefitted
from the experience.
-
Jul 12, 2023 | 
mondaq.com | Kate Driscoll
Kate Driscoll authored an article with Veronica Ip, Associate
General Counsel at McKinsey & Company, sharing what they
learned from their secondment experience and providing a blueprint
that other in-house legal teams considering secondments might
follow in the future.
Last year, the Litigation & Investigations team at McKinsey
instituted its first ever secondment program when Veronica went on
parental leave. Kate was onboarded to take over Veronica's role
while she was out.
-
Apr 25, 2023 | 
jdsupra.com | Adam L. Braverman |Kate Driscoll |Nathaniel Mendell
On March 28, 2023, the U.S. Court of Appeals for the Sixth Circuit issued a decision in U.S. ex rel. Martin v. Hathaway limiting the scope of liability under the Anti-Kickback Statute (AKS) and the False Claims Act (FCA) in two ways. First, the Sixth Circuit narrowly interpreted “remuneration” under the AKS to mean “payments or other transfers of value,” as opposed to “any act that may be valuable” to another.
